Skip to main content

Table 3 Baseline disease characteristics of the per protocol population

From: Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

Mean (SD) Placebo (n = 7) Namilumab 150 mg (n = 7) Namilumab 300 mg (n = 7) Total (N = 21)
DAS28-ESR 4.7 (0.33) 4.9 (0.35) 4.4 (0.59) 4.7 (0.47)
DAS28-CRP 4.0 (0.35) 4.4 (0.33) 4.0 (0.62) 4.1 (0.46)
ESR, mm/hour 31.3 (7.43) 27.7 (5.94) 23.0 (8.06) 27.3 (7.66)
CRP, mg/liter 16.4 (25.09) 9.1 (6.42) 11.5 (10.44) 12.2 (14.91)
TJC (0–68) 6.6 (2.15) 10.0 (6.98) 9.6 (4.69) 8.7 (5.00)
SJC (0–66) 3.4 (1.4) 4.7 (2.14) 6.1 (5.3) 4.8 (3.42)
PGA for pain 54.6 (14.9) 58.4 (21.1) 50.1 (16.7) 54.3 (17.5)
PGA of DAS 42.4 (21.1) 59.9 (19.3) 43.3 (16.4) 39.5 (18.9)
  1. CRP C-reactive protein, DAS disease activity score, ESR erythrocyte sedimentation rate, PGA patient global assessment, SD standard deviation, SJC swollen joint count, TJC tender joint count